Survey unveils India’s rising tide of metabolic diseases
April 23, 2024 / Metabolic Disease / Diabetes / India / Hypertension
A comprehensive survey by the Indian Council of Medical Research reveals a high prevalence of metabolic diseases such as diabetes, hypertension, obesity, and dyslipidemia across India, with notable differences between urban and rural areas and among different states.
Identification of key genes involved in the alleviative effects of Polysaccharide of Atractylodes macrocephala Koidz on high-fat diet-induced nonalcoholic fatty liver disease in mice
April 23, 2024 / NAFLD / Metabolic Health / Liver Treatment
Research demonstrates that Polysaccharide of Atractylodes macrocephala Koidz (PAMK) alleviates non-alcoholic fatty liver disease (NAFLD) in mice by influencing metabolic and inflammatory pathways, suggesting its potential as a dual-action treatment.
Why protecting the heart and kidneys is vital in managing type 2 diabetes
April 23, 2024 / Diabetes / Cardiovascular Risk / Kidney Disease / Cardiorenal Syndrome
Dr. Mohamed Meshref emphasizes the importance of a comprehensive approach to managing type 2 diabetes (T2D) that includes attention to cardiovascular and renal health due to the interconnected nature of these systems, highlighting the need for holistic treatment strategies.
Dr Diana Isaacs Surveys Emerging Diabetes, Obesity, and Cardiometabolic Treatment Landscape
April 24, 2024 / GLP-1 Receptor / Cardiometabolic Health / Diabetes / Glucose Monitoring
Dr. Diana Isaacs highlighted significant advances and challenges in treating diabetes, obesity, and cardiometabolic diseases during a recent event. She emphasized the impact of GLP-1 receptor agonists and continuous glucose monitoring, while addressing issues related to cost, access, and medication shortages.
Risk of cancer history in cardiovascular disease among individuals with hypertension
April 24, 2024 / Hypertension / Cancer Risk / Cardiovascular Disease
A study involving 747,620 individuals with hypertension found that those with a history of cancer, especially those who underwent chemotherapy, had a significantly higher risk of cardiovascular disease events compared to those without cancer.
Relacorilant shows significant benefits in Cushing’s patients in trial
April 24, 2024 / Cushing’s Syndrome / High Blood Pressure / Treatment
A Phase 3 trial of relacorilant showed significant benefits in reducing high blood pressure and blood sugar in patients with endogenous Cushing’s syndrome, indicating its potential as a new standard treatment without significant safety concerns.
FDA Approves Pivya for Uncomplicated UTIs
April 24, 2024 / FDA / UTI
The FDA has approved pivmecillinam (Pivya) for treating uncomplicated urinary tract infections in adult women caused by certain bacteria. Clinical trials demonstrated its efficacy in alleviating symptoms and reducing bacteria compared to placebo and other treatments.
Fatty acid binding protein 5 suppression attenuates obesity-induced hepatocellular carcinoma by promoting ferroptosis and intratumoral immune rewiring
April 25, 2024 / Obesity / Cancer Treatment
Suppressing fatty acid binding protein 5 (FABP5) in obesity-induced hepatocellular carcinoma (HCC) can reduce tumor burden by promoting ferroptosis and enhancing immune activity within tumors, offering a potential therapeutic strategy.
Study identifies driver of liver cancer that could be target for treatment
April 25, 2024 / Liver Cancer / Fatty Liver Disease / Cancer Treatment
Yale researchers discovered that inhibiting fatty acid binding protein 5 (FABP5) could potentially halt liver cancer progression, driven by obesity-related non-alcoholic fatty liver disease, by promoting ferroptosis and altering the tumor microenvironment.
Study finds being overweight is associated with alterations in brain pulsations
April 25, 2024 / BMI / Brain Pulsation / Obesity / Metabolic Health
A study by the University of Oulu found that a high body mass index (BMI) alters crucial brain pulsations, which could disrupt brain fluid circulation and metabolic waste clearance, potentially affecting brain function and increasing neurological risks.
Food additive emulsifiers linked to increased risk of type 2 diabetes
April 25, 2024 / Type 2 Diabetes / Metabolic Health
Research from The Lancet Diabetes & Endocrinology links certain food additive emulsifiers, like carrageenans and guar gum, to an increased risk of type 2 diabetes, highlighting the need for reevaluation of regulatory standards.
Investigation of Markedly Elevated Liver Enzymes With Serendipitous Underlying Wilson’s Disease With Chronic Alcohol Abuse
April 25, 2024 / Wilson’s Disease / Alcohol-induced liver damage / Liver Disease
A study explored a case where a patient with a history of chronic alcohol abuse presented with severe liver enzyme elevation. Further investigation revealed Wilson’s disease as a potential underlying cause, highlighting the complexity of diagnosing liver disorders.
People with rare longevity mutation may also be protected from cardiovascular disease
April 26, 2024 / Cardiovascular Health / Laron Syndrome / Growth Hormone / Insulin
Individuals with growth hormone receptor deficiency (GHRD), or Laron syndrome, may have reduced cardiovascular disease risk despite elevated LDL cholesterol, featuring lower blood pressure, insulin resistance, and reduced carotid artery thickness.
Renibus Therapeutics Announces Oral Presentations on RBT-1 at AATS and SCA Medical Conferences
April 26, 2024 / Renibus Therapeutics / Cardiothoracic Surgery / FDA / Clinical Trials
Renibus Therapeutics presented clinical data on RBT-1, a preconditioning agent for reducing post-operative complications in cardiac surgery, at the AATS and SCA medical conferences, emphasizing the ongoing PROTECT Phase 3 trial’s progress.
Women more likely to develop new disorders after Cushing’s remission
April 26, 2024 / Women’s Health / Crushing’s Syndrome / Autoimmune Disorders
Women are more likely than men to develop new health issues, including autoimmune disorders, within a year of entering remission from Cushing’s syndrome, highlighting the need for vigilant post-remission monitoring.
Metabolic Syndrome Frequency in Type 2 Diabetics Using International Diabetes Federation (IDF) Criteria Analysis
April 27, 2024 / Metabolic Syndrome / Diabetes / Cardiovascular Risks / Blood Pressure / Metabolic Health
A study at Chandka Medical College found that 87.2% of type 2 diabetics had metabolic syndrome as per IDF criteria, highlighting strong associations with gender, blood pressure, and HDL cholesterol levels but not with age or serum triglycerides.
Brown Fat’s “Off Switch” Discovery Combats Obesity
April 29, 2024 / AC3-AT Protein Obesity / Obesity Treatment / Calories
Research identifies AC3-AT protein as a regulator that inhibits brown adipose tissue (BAT) activity, potentially limiting its role in combating obesity. Blocking this “off switch” may enhance BAT’s calorie-burning properties and aid obesity treatment.
What’s Next for Obesity Therapeutics? Higher Quality Weight Loss
April 29, 2024 / Obesity Therapeutics / Weight Loss / GLP-1 agonists
The biopharma industry is advancing beyond current GLP-1 agonists by developing treatments that promote higher-quality weight loss, reducing muscle loss and enhancing metabolic benefits to combat obesity more effectively.
Are Obesity Meds Widening Health Disparity Gaps?
April 29, 2024 / GLP-1 Agonist / Obesity Treatment / Obesity Drugs
New obesity medications, particularly GLP-1 agonists, show promise in treating chronic diseases related to obesity but are hindered by high costs, limiting access for those most in need and potentially widening health disparities.
Young adults with HIV have high prevalence of heart disease risk factors
April 29, 2024 / HIV / Cardiovascular Risk / Metabolic Disorders
Young adults with perinatally acquired HIV exhibit high rates of metabolic disorders like diabetes and elevated cholesterol, necessitating vigilant long-term cardiovascular monitoring due to increased risk factors present from early antiretroviral exposure.
Osteoporosis in a Woman With Multiple Sclerosis: A Case Report
April 29, 2024 / Case Study / Multiple Sclerosis / Autoimmune Bone Metabolism / Osteoporosis
A case study explores a 63-year-old woman with multiple sclerosis who developed severe osteoporosis and suffered multiple fractures, including a periprosthetic femoral fracture, despite receiving osteoporosis treatment.